Serina Therapeutics, Inc. (SER) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US81751A1088
Serina Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 130,000.00 USD |
| Operating income | -24.02 m USD |
| EBIT | -18.98 m USD |
| Net income | -19.18 m USD |
| Diluted EPS – continuing operations | -1.91 USD |
Full history since 2016, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has completed phase 1a clinical trial. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. It has a partnership agreement with Gannet BioChem to support development activities for SER-252. Serina Therapeutics, Inc. was founded in 2006 and is headquartered in Huntsville, Alabama.
More stocks
- BLUE BIOFUELS, INC. (BIOF)
- TaiRx, Inc. (6580.TWO)
- Hanchem Co,. Ltd. (457370.KQ)
- Laredo Oil, Inc. (LRDC)
- ELUTIA INC. (ELUT)
- Biomea Fusion, Inc. (BMEA)
- Organto Foods Incorporated (OGO.V)
- EXOZYMES INC. (EXOZ)
- Sino Green Land Corp. (SGLA)
- Fair Value REIT-AG (FVI.F)
- Model Solution Co., Ltd. (417970.KQ)
- Luminescence Technology Corp. (6729.TWO)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.